Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dublin, Sept. 25, 2019 (GLOBE NEWSWIRE) -- The "Cardiovascular Drugs Global Market Forecast To 2022" report has been added to ResearchAndMarkets.com's offering. Where is the largest...
-
Dublin, Sept. 25, 2019 (GLOBE NEWSWIRE) -- The "Pharmaceuticals Global Market Forecast To 2022" report has been added to ResearchAndMarkets.com's offering. Where is the largest and...
-
Portland, OR, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The global BCG vaccines sales market was accounted for $45.5 million in 2017 and is projected to reach $65.92 million by 2025, registering a CAGR of...
-
New York, NY, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Overactive Bladder Treatment Market By Pharmacotherapy (Anticholinergic, Botox, and Others)...
-
Dublin, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Polyene Phosphatidylcholine Market, 2019-2023" report has been added to ResearchAndMarkets.com's ...
-
Dallas, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- The “Global Acquired Hemophilia Treatment Market Size 2018 by Therapy (Inhibitor Eradication Therapy and Hemostatic Therapy), by Region and Forecast...
-
INNATE PHARMA ANNONCE LA PRÉSENTATION DE DONNÉES CLINIQUES SUR IPH5401 ET MONALIZUMAB AU CONGRÈS DE L’ESMO 2019 Données préliminaires issues de STELLAR-001, l’étude de Phase I en escalade de dose...
-
INNATE PHARMA ANNOUNCES CLINICAL DATA PRESENTATIONS ON IPH5401 AND MONALIZUMAB AT ESMO 2019 Preliminary results of IPH5401 STELLAR-001, a dose escalation Phase I study in patients with advanced solid...
-
Innate Pharma files registration statement for proposed initial public offering in the United States
Marseille, France, September 20, 2019 INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“Innate” or the “Company”), a French biotechnology company focused on discovering, developing and...
-
Marseille, France, le 20 septembre 2019, 23:30 INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (« Innate » ou la « Société »), une société de biotechnologie française spécialisée dans...